表紙
市場調査レポート

米国の経皮パッチ市場と治験分析

US Transdermal Patch Market & Clinical Trial Insight

発行 KuicK Research 商品コード 344406
出版日 ページ情報 英文 300 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
米国の経皮パッチ市場と治験分析 US Transdermal Patch Market & Clinical Trial Insight
出版日: 2015年11月03日 ページ情報: 英文 300 Pages
概要

米国は、世界の他の市場と比較しても、経皮パッチの消費者基盤がきわめて高くなっています。女性用避妊薬、ニコチン置換療法 (NRT) など、この数年間で多くの注目を集めるようになりました。インスリンパッチ、ワクチンパッチは、現在、治験の段階にありますが、今後数年間のうちに製品化が期待されています。

当レポートでは、米国の経皮パッチ市場について調査分析し、市場概要、バリューチェーン分析、医薬品製造受託機関 (CMO) 、臨床パイプライン分析、臨床パイプライン、前臨床段階の主要製品、上市済み製品など、体系的な情報を提供しています。

第1章 経皮パッチの概要

第2章 経皮パッチの種類

  • 単層/多層式の薬剤入り接着剤
  • リザーバー型の経皮パッチ
  • マトリックス型の経皮パッチ
  • 蒸気パッチ
  • アクティブ/パッシブパッチ

第3章 経皮パッチのドラッグデリバリーのメカニズム

第4章 経皮パッチの利点

第5章 米国の経皮パッチ市場の概要

  • 現在の市場シナリオ
  • 経皮パッチの臨床パイプラインの概要

第6章 ジェネリック/ブランドの経皮パッチ

第7章 米国の経皮パッチ市場:バリューチェーン分析

  • 研究開発
  • 製造
  • マーケティング・流通
  • エンドユーザー価格

第8章 米国の経皮パッチCMO

第9章 米国の経皮パッチ市場成長促進要因

  • パーキンソン病
  • アルツハイマー病
  • 女性用避妊薬
  • ニコチン置換療法 (NRT)
  • インスリン
  • ワクチン

第10章 米国の経皮パッチ市場情勢

  • 好ましい市場パラメーター
  • 商業化の課題

第11章 米国の経皮パッチ市場の将来見通し

第12章 米国の経皮パッチ臨床パイプライン分析:企業別、適応別、相別

  • 研究段階
  • 前臨床段階
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 申請済み
  • 承認済み

第13章 上市済みの経皮パッチ臨床分析:企業別、適応別

第14章 開発が中断/中止された経皮パッチ臨床分析:企業別、適応別、相別

  • 開発報告なし
  • 中断
  • 市場撤退
  • 中止

第15章 競合情勢

  • 3M Pharmaceuticals
  • Acrux
  • Agile Therapeutics
  • Allergan
  • ANI Pharmaceuticals
  • Antares Pharma
  • Bayer HealthCare Pharmaceuticals
  • Corium International
  • Chase Pharmaceuticals
  • DURECT Corporation
  • Endo Pharmaceuticals
  • Fempharm
  • 久光製薬
  • Immune Pharmaceuticals
  • Imprimis Pharmaceuticals
  • Ipsen Bioscience
  • Johnson & Johnson
  • LaSalle Laboratories
  • Lavipharm-increase
  • MINRAD International
  • NeurogesX
  • Noven Pharmaceuticals
  • NuPathe
  • Nuvo Research
  • Novartis
  • Pain Therapeutics
  • ProStrakan
  • Purdue Pharma
  • Sanofi
  • Scilex Pharmaceuticals
  • 千寿製薬
  • Somerset Pharmaceuticals
  • 帝國製薬
  • Therapeutic Discovery Corporation
  • Transdermal Delivery Solutions
  • UCB
  • Xel Pharmaceuticals
  • Zosano Pharma
目次

Innovations in pharmaceutical industry have a long track record of showing commercialization potential with respect to emerging and feasible technology. In US, such innovations have high level of acceptance among various stake holders of the pharmaceutical industry. Transdermal patches have emerged as one such innovations which have rich history but main development has been observed in past decade. They have been improved from a mere piece of tape dipped in formulation to complex matrix system containing therapeutics offering higher control over drug delivery. Long-term usage, high cost-effectiveness, high compliance rates and easy availability are some of the major factors behind the growth of transdermal patches in US.

Consumer base for transdermal patches is quite high in US in comparison to other markets across the globe. Segments like female contraceptives and Nicotine Replacement Therapy (NRT) have received lots of attention in past years. Indications like Parkinson's disease and Alzheimer's disease have few transdermal patches and have unexplored opportunities in US market. While Insulin and vaccine patches are at different stages of clinical trials which would be introduced in coming years. Unexplored disease segments have less competition and lack of transdermal patches makes them suitable choice for potential transdermal patch developers. This scenario suggests that US transdermal patch market has lots of commercialization opportunities that have to be reaped in coming years.

Some of the transdermal patches have completed their product life cycle and have given way to generic transdermal patches. Several small/mid-sized transdermal patch developers can take benefit of this scenario. Side-by-side, transdermal manufacturers have developed capabilities to customize products according to client's necessities. Improvement of transdermal patch technology is also expected to place as material science and associated fields are also developing. These observations suggest that US transdermal patch market will offer several commercialization opportunities. In this way, US transdermal patch segment shows progress at every level reflecting that this segment is expected to grow several folds in coming years.

“US Transdermal Patch Market & Clinical Trial Insight” Report Highlights:

  • US Transdermal Patch Market Overview
  • Generic & Branded Transdermal Patches
  • US Transdermal Patch Market: Value Chain Analysis
  • US Transdermal Patch Contract Manufacturing Organization
  • US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
  • US Transdermal Patch Clinical Pipeline: 55 Patches
  • Majority Patches in Preclinical Phase: 27 Patches
  • Marketed Transdermal Patch Clinical Insight by Company & Indication
  • Marketed Transdermal Patches in US: 33 Patches

Table of Contents

1. Introduction to Transdermal Patch

2. Types of Transdermal Patches

  • 2.1. Single/ Multiple-Layer Drug-in-Adhesive
  • 2.2. Reservoir Transdermal Patches
  • 2.3. Matrix Based Transdermal Patches
  • 2.4. Vapor Patch
  • 2.5. Active and Passive Patch

3. Mechanism of Transdermal Patch Drug Delivery

4. Advantages of Transdermal Patch

5. US Transdermal Patch Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Transdermal Patch Clinical Pipeline Overview

6. Generic & Branded Transdermal Patches

7. US Transdermal Patch Market: Value Chain Analysis

  • 7.1. Research & Development
  • 7.2. Manufacturing
  • 7.3. Marketing & Distribution
  • 7.4. Price to End User

8. US Transdermal Patch Contract Manufacturing Organization (CMO)

9. US Transdermal Patch Market Growth Frontiers

  • 9.1. Parkinson's Disease Transdermal Patch
  • 9.2. Alzheimer's Disease Transdermal Patch
  • 9.3. Female Contraceptive Transdermal Patch
  • 9.4. Nicotine Replacement Therapy Transdermal Patch
  • 9.5. Insulin Transdermal Patch
  • 9.6. Vaccine Transdermal Patch

10. US Transdermal Patch Market Landscape

  • 10.1. Favorable Market Parameters
  • 10.2. Commercialization Challenges

11. US Transdermal Patch Market Future Prospects

12. US Transdermal Patch Clinical Pipeline Insight by Company,Indication & Phase

  • 12.1. Research
  • 12.2. Preclinical
  • 12.3. Phase-I
  • 12.4. Phase-I/II
  • 12.5. Phase-II
  • 12.6. Phase-III
  • 12.7. Preregistration
  • 12.8. Registered

13. Marketed Transdermal Patch Clinical Insight by Company & Indication

14. Discontinued & Suspended Transdermal Patch Clinical Insight by Company, Indication & Phase

  • 14.1. No Development Reported
  • 14.2. Discontinued
  • 14.3. Market Withdrawal
  • 14.4. Suspended

15. Competitive Landscape

  • 15.1. 3M Pharmaceuticals
  • 15.2. Acrux
  • 15.3. Agile Therapeutics
  • 15.4. Allergan
  • 15.5. ANI Pharmaceuticals
  • 15.6. Antares Pharma
  • 15.7. Bayer HealthCare Pharmaceuticals
  • 15.8. Corium International
  • 15.9. Chase Pharmaceuticals
  • 15.10. DURECT Corporation
  • 15.11. Endo Pharmaceuticals
  • 15.12. Fempharm
  • 15.13. Hisamitsu Pharmaceutical
  • 15.14. Immune Pharmaceuticals
  • 15.15. Imprimis Pharmaceuticals
  • 15.16. Ipsen Bioscience
  • 15.17. Johnson & Johnson
  • 15.18. LaSalle Laboratories
  • 15.19. Lavipharm-increase
  • 15.20. MINRAD International
  • 15.21. NeurogesX
  • 15.22. Noven Pharmaceuticals
  • 15.23. NuPathe
  • 15.24. Nuvo Research
  • 15.25. Novartis
  • 15.26. Pain Therapeutics
  • 15.27. ProStrakan
  • 15.28. Purdue Pharma
  • 15.29. Sanofi
  • 15.30. Scilex Pharmaceuticals
  • 15.31. Senju Pharmaceutical
  • 15.32. Somerset Pharmaceuticals
  • 15.33. Teikoku Seiyaku
  • 15.34. Therapeutic Discovery Corporation
  • 15.35. Transdermal Delivery Solutions
  • 15.36. UCB
  • 15.37. Xel Pharmaceuticals
  • 15.38. Zosano Pharma
Back to Top